

**CLINICAL PRIORITIES ADVISORY GROUP
04 12 18**

| | |
|---------------------------------|--------------|
| Agenda Item No | |
| National Programme | Trauma |
| Clinical Reference Group | Neuroscience |
| URN | 170109S |

| |
|--|
| Title |
| Adult Neurosurgery Service Specification |

| | |
|--------------------------|--|
| Actions Requested | 1. Support the adoption of the service specification |
| | 2. Recommend its approval as an IYSD |

| |
|--|
| Proposition |
| <p>This is a revised and updated service specification to replace the current publication. CPAG are requested to agree and recommend the changes to this updated service specification for adult neurosurgery.</p> <p>This specification tightens up the language to make it more user friendly and removes unnecessary duplication.</p> |

| |
|--------------------------------------|
| Clinical panel recommendation |
| Not applicable. |

| | |
|---|---|
| The committee is asked to receive the following assurance: | |
| 1. | The Head of Clinical Effectiveness confirms the proposal has completed the appropriate sequence of governance steps. |
| 2. | The Head of Acute Programmes confirms the proposal is supported by an: Impact Assessment; Stakeholder Engagement Report; Consultation Report; Equality Impact and Assessment Report; Service Specification. The relevant National Programme of Care has approved these reports. |
| 3. | The Director of Finance (Specialised Commissioning) confirms that the impact assessment has reasonably estimated a) the incremental cost and b) the budget impact of the proposal. |
| 4. | The Operational Delivery Director (Specialised Commissioning) confirms that the service and operational impacts have been completed. |
| 5. | The Director of Nursing (Specialised Commissioning) confirms that the proposed quality indicators have been adequately defined. |

| The following documents are included (others available on request): | |
|--|--|
| 1. | Service specification Proposition |
| 2. | Consultation Report |
| 3. | Evidence Summary – not applicable |
| 4. | Clinical Panel Report - not applicable |
| 5. | Equality Impact and Assessment Report |

| The Benefits of the Proposition | | |
|--|--|-------------------------------------|
| <i>No</i> | <i>Metric</i> | <i>Summary from evidence review</i> |
| 1. | Survival | Not measured |
| 2. | Progression free survival | Not measured |
| 3. | Mobility | Not measured |
| 4. | Self-care | Not measured |
| 5. | Usual activities | Not measured |
| 6. | Pain | Not measured |
| 7. | Anxiety / Depression | Not measured |
| 8. | Replacement of more toxic treatment | Not measured |
| 9. | Dependency on care giver / supporting independence | Not measured |
| 10. | Safety | Not measured |
| 11. | Delivery of intervention | Not measured |

| Considerations from review by Rare Disease Advisory Group |
|--|
| Not Applicable. |

| Pharmaceutical considerations |
|--------------------------------------|
| Not Applicable. |

| Considerations from review by National Programme of Care |
|---|
| |

The revised specification received the support of the Trauma PoC Board on the 6th July 2018.

There is no financial model for this revised specification as it does not change the service delivery for neurosurgery and is therefore cost neutral.